Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
July 2015
-
How I built a mini-gut with next to no biology training
-
Rewriting the playbook for clinical testing in a rare disease
A Novartis team blazes new trails with an experimental treatment for spinal muscular atrophy.
-
Media Release
Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization
First in the world approval brings hope of longer life and fewer hospitalizations for millions of Americans with heart failure with reduced ejection fraction Entresto is the first and only treatment… -
Surviving with heart failure
Heart failure affects 26 million people worldwide. Half die within five years of diagnosis. There's been a lack of progress in finding more effective medications. Advances in understanding mean new options for patients and caregivers.
-
Media Release
Alcon receives European Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery
AcrySof® IQ Aspheric Intraocular Lens (IOL) with UltraSertTM Pre-loaded Delivery System helps to maintain the integrity of the incision while facilitating smooth, consistent delivery of the IOL…
June 2015
-
Media Release
Novartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watches
New features of the ViaOpta apps, previously available for iPhone and AndroidTM mobile phones, are also available to enhance the daily lives of people with visual impairments These apps… -
Media Release
Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc.
Acquisition adds novel angiotensin II Type 2 receptor antagonist for the treatment of neuropathic pain to Novartis' industry-leading development pipeline Neuropathic pain is a chronic… -
Media Release
Novartis announces publication in The Lancet showing sustained efficacy with secukinumab over one year in psoriatic arthritis patients
In the FUTURE 2 study, secukinumab demonstrated rapid onset of action, was significantly superior to placebo in improving signs and symptoms of psoriatic arthritis (PsA), with efficacy sustained… -
Media Release
Novartis drug Farydak® recommended by CHMP for EU approval to treat multiple myeloma, providing patients a new mechanism of action
Farydak (panobinostat) combination improved PFS by 7.8 months for patients who received >=2 prior regimens including bortezomib and an IMiD[1] Farydak would be the first HDAC inhibitor with… -
Media Release
Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg
Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Sandoz has begun shipping to US customers… -
Health collaboration in Russia helped reduce blood pressure, deaths
Novartis worked with doctors, patients and government officials in the Yaroslavl region of Russia to address high death rates from stroke and heart disease.
-
Media Release
Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day
Strong progress on innovation across divisions Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and…
Pagination
- ‹ Previous page
- 1
- …
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- …
- 154
- › Next page
Test disclaimer...!!!